Brought to you by 
ZymoGenetics licenses clotting factor to Novo Nordisk
11 Jan 2010
Executive Summary
With hopes to free up resources for other projects while still benefiting from future economic returns, ZymoGenetics (protein therapeutics) has licensed to Novo Nordisk exclusive worldwide rights to its recombinant Factor XIII (rFactor XIII) and all related intellectual property.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ZymoGenetics licenses clotting factor to Novo Nordisk
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice